[{"title": "Plus Therapeutics Turns Profitable as New Cancer Detection Tool Readies for Launch - Stock Titan", "description": "<a href=\"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOU01ySGt1WXlVaTc0cVVucVdPTXBsRS1Ea0RGREZOMGV1VEdjdVhiOFY5MHY5NnFmcVU1bTlJazRPaktqWi1FWmpMVXVDNlBRY3l1ZEJubmdJbm9rQzB6LVJmbzNQREtYM2RtV0lWWUJQa2h0dDZrYlEwMzdIUHc2RVdLLXJpRk11RXB4TWgxNUhsTDFGQTRfNW5SN0VhX1JNeTE5UkNydkY4Wk9FbmhORTRrZjE3TGln?oc=5\" target=\"_blank\">Plus Therapeutics Turns Profitable as New Cancer Detection Tool Readies for Launch</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Stock Titan</font>", "publishedAt": "Thu, 14 Aug 2025 20:15:00 GMT"}, {"title": "Plus Therapeutics receives extension to meet Nasdaq listing requirements - Investing.com", "description": "<a href=\"https://news.google.com/rss/articles/CBMixwFBVV95cUxOMnVEbkVjOTRLYURfdUNXSE5ILXdkWGhialM5WUdDNW5SYTlvTm9GRmx2bktJbWQzc0RLdW9ObkNuSEhjZm9UeV9GMVJ3aEkwS1FEYlVjU3ZHRm9wakkxRTlwdTBNOVpqMnlOMjRyRTF0d1g0RUFMWWRKT21OVWsyR2xGYU45V2RUSEk2T0pETWpQN09YU1Q5Sl8ybWR3TUpUQ0JFSlR6dTlaT18zNWtWMVl4d2tlSHZWazNYTDVQdmxHcXR4WFhr?oc=5\" target=\"_blank\">Plus Therapeutics receives extension to meet Nasdaq listing requirements</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Investing.com</font>", "publishedAt": "Wed, 13 Aug 2025 10:35:51 GMT"}, {"title": "Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights - Yahoo Finance", "description": "<a href=\"https://news.google.com/rss/articles/CBMijwFBVV95cUxPMThmY0R2aGwyQ3V5OFZmVll6WmlWRndGMGNUUUhwcjBudE1kYzB3Rm02RWFCYmxRM0lvaTZZbS1ENG1CeFdtLVRUZDh3X2ViQWhrUWNGbGZhU2NMa2FmTVVKd09mNU4xT3gzWDBLNExvZ1RMT084ZjIwZjc4VV9MTmV0UGRUTFhLZEJZekEwOA?oc=5\" target=\"_blank\">Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>", "publishedAt": "Thu, 14 Aug 2025 20:15:00 GMT"}, {"title": "Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates - Nasdaq", "description": "<a href=\"https://news.google.com/rss/articles/CBMimwFBVV95cUxPal8tOEVKUXdxOU9hYUVYb0F4Ulh5aEpXUGRHakpYWmh5UXcxbkxQX2VXd3o5QVA2bm5GZnlmUmRKanFnYkgyX2VkSVkyR1FkQXJlX25FeDROb3o3SEVGc053QjhOSHQyZ25acEZsNU9Ub3NvemR5QzRyVlNTb3prUFM2TU9TalB0TjdoOWpEdkFFODBoOFNLZl9IUQ?oc=5\" target=\"_blank\">Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Nasdaq</font>", "publishedAt": "Thu, 14 Aug 2025 21:30:00 GMT"}, {"title": "Plus Therapeutics Approves Key Proposals at Annual Meeting - TipRanks", "description": "<a href=\"https://news.google.com/rss/articles/CBMirwFBVV95cUxQWkRveVdhN1JGY045ekR1eXo4UlktbEdrMEJsbWdKaUhPUGlsMmZtX3lyVHhqSTJ1NGlvMkVmT3d4cWhRQkVkZzB5c0k4aDFUSEFVZElwWk5VeXZOYlQxdGFXa0NIU2hCS3JDV05hUXAwQ2U3Z1B4RXlxVXdsTlRNVHdJWUNaS2l5Wm96WjhxMnoxSjJxRTFIRGNJa05iemdqS3lrYmstY0QwQXBTU0JB?oc=5\" target=\"_blank\">Plus Therapeutics Approves Key Proposals at Annual Meeting</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TipRanks</font>", "publishedAt": "Tue, 12 Aug 2025 21:21:58 GMT"}, {"title": "Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingView", "description": "<a href=\"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPSFpnTTZ2bmgxdllfaGNoMmZhY1Y1NmxrbDV0bkdRSzMzMzB1WmdtMlZ0Q0xMRmZIa0lMbTlGVm1SRWdfRDBaczVDN0hvRnYzcnc3b1I3TFNPOUNaeU5XRW9tOVU5ZW9kczNnbkFaelc4RW1ocGlhUnlDay1XSms2OW40c1dzZ0VPYzBNRXQzaW11Uk92OF9EMm5WUEFPVTlGVUVfZzJESERiS3luQmxIUjJSYnhLd2h4NjhXNHdPRDI0OXZjVUJHZU44NzEzZGYtNmlKdUlRWGswR0h3WkVtWkxXMUt4SERaZnc?oc=5\" target=\"_blank\">Plus Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TradingView</font>", "publishedAt": "Thu, 14 Aug 2025 21:41:44 GMT"}, {"title": "Plus Therapeutics Granted Continued Nasdaq Listing with Conditions - AInvest", "description": "<a href=\"https://news.google.com/rss/articles/CBMilgFBVV95cUxNODc1UWdDeHdQX0RhakJKWkdWcElmOG1Iemc4YU1WQXIzX0c3MEREZVdpS3BiZGZrM29MT2pmNHdpbUd6TTkzdGJ0RDllX0ZOd2htOUt3WTJzV0JaM19GdnpZY3YzeERidU5ZaTl6TGtHalpGV1R2Yk1hLUpTQldrS1R4QnZPbkkzQ2c0NFMxZ05hWllkX1E?oc=5\" target=\"_blank\">Plus Therapeutics Granted Continued Nasdaq Listing with Conditions</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">AInvest</font>", "publishedAt": "Thu, 14 Aug 2025 01:35:42 GMT"}, {"title": "Plus Therapeutics Reports Stockholders\u2019 Equity in Excess of - GlobeNewswire", "description": "<a href=\"https://news.google.com/rss/articles/CBMilwJBVV95cUxPMUt4TkRRZlpMekpFY1d1V21yckpMdTNZYjB0M3hidWxnQ0ZkREZNd3dsTEhKUFhYdVFYX1lGVlpmQ0ZfTEpJblNaczVhT0hBOVpKS2ZKZ2k2MEZVZjUwUnViT3VrOTlzby00MlItWkVuQ21FdWg1VEFHN1J1RWY1YUdEYXRRV1U5Q0YtQ1M1Z2FBWEVaWWkzYXNSNlkweVRWUjg0UFlWNnZPODF5OWdzUUIySmFXWUEwM1ZCSEQ2M1ZNTUpkZ0lIYzVMa1diTUl4by16UmZtcTVqbS1JUjZXUklZaFA4ZFBRc0FjM21uZW1tY21Ud0F1dXU1WFR0RTE5UlQtMVFNOVpNZlRfUUtRUGNmYlFnXzg?oc=5\" target=\"_blank\">Plus Therapeutics Reports Stockholders\u2019 Equity in Excess of</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">GlobeNewswire</font>", "publishedAt": "Fri, 15 Aug 2025 11:31:21 GMT"}, {"title": "$3M Equity Achievement: Plus Therapeutics CNS Cancer Drug Developer Maintains Nasdaq Listing Status - Stock Titan", "description": "<a href=\"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOUmRTNVNQOFJrVDFsVF85V0dodjV0SUljdmp1NC05aWpnRUpYQkZVLVlmV3FicFN0TU1mRnNjZHZwaUxUV2c2Q1lUcUtTdkM3WUJFS1QwZXVnTGJyZHFLV19rVnBwVzB6dDM5WWZHS0JJdjlVbC1yYTZDaGRYTG5FZWRGaUxPaThFWU8zbTBmLWxrSUhyUm1xWFBlS0ZIRnJrVGRPdGJhUEkzU292X2ttS3hWVDRvWlBX?oc=5\" target=\"_blank\">$3M Equity Achievement: Plus Therapeutics CNS Cancer Drug Developer Maintains Nasdaq Listing Status</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Stock Titan</font>", "publishedAt": "Fri, 15 Aug 2025 11:30:00 GMT"}, {"title": "Plus Therapeutics meets Nasdaq equity requirement to maintain listing - Investing.com", "description": "<a href=\"https://news.google.com/rss/articles/CBMixAFBVV95cUxOeFRSTDhjVk1LcDZrVHJVZmtDQktxNktTNTZ5VEpXRkJFNXBQQ1VJVFd2S1I0WGYwMlhmYW85YVJjeFh4M0plaFNwM0FIc1NXalMyU1gwU2dvQV9wcWsxMXdJOWVTcUVuQThQc05FY21aS011enMxQVN3RTd1bDVPSHhHaThwREI5T3RuRndOd1pLZkNMb21JTkNnMWljQVpYamUydlRpTzBHcHRHdDRwRGdlak5Mc3gtRHY5a2JaVV95ZVRp?oc=5\" target=\"_blank\">Plus Therapeutics meets Nasdaq equity requirement to maintain listing</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Investing.com</font>", "publishedAt": "Fri, 15 Aug 2025 11:52:21 GMT"}, {"title": "Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference - Yahoo Finance", "description": "<a href=\"https://news.google.com/rss/articles/CBMikgFBVV95cUxOclI4Uzdaanl0TklPM2phSFQzUEhBSG5Jc0JscmpZZHoyNF9KN3V6VGd6Vy1uMXg3eDVtaTNIdUdJNno4akFSYXhwLWk0YUxyZEVPU0E5aWgySlFqMHJaV21QOTJielN1VWN5N0ZLeTVFVGpucl9oTk9MdGlhOUJwYVJhOFM3cFhERVJFc1NrMDRRZw?oc=5\" target=\"_blank\">Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>", "publishedAt": "Thu, 14 Aug 2025 11:30:00 GMT"}, {"title": "Plus Therapeutics Reports Satisfactory Equity, Avoids Nasdaq Delisting - AInvest", "description": "<a href=\"https://news.google.com/rss/articles/CBMioAFBVV95cUxPc1U1U1ZZYWJkWWc0eG1CWVJJNlltYjBVWklRMTUzb1FqZWFJWlhXNVpOdk5SWUtHZmFrN2pITEJVajJNOTZXWThRR2YtdlVmMTJBbjlEamdBUi1WZjBYYWozbUl5TlR6b3N3X0ZTOEtFVVRZSmpkRmpUS3BXRHYzREpjSG5WUFRMNzJUWE9HbzFHbktESVRnbzVvYUhKU1VP?oc=5\" target=\"_blank\">Plus Therapeutics Reports Satisfactory Equity, Avoids Nasdaq Delisting</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">AInvest</font>", "publishedAt": "Fri, 15 Aug 2025 11:32:33 GMT"}, {"title": "Plus Therapeutics (PSTV) Falls After Mixed Q2 Results and Secondary Offering - GuruFocus", "description": "<a href=\"https://news.google.com/rss/articles/CBMiswFBVV95cUxPOXpkLXJXUmtZU3l3N3NvbXFaOXNUai1QcWcwV0JJempNZE9oemVxdkEyVW95QkxsR2RQei1ZUDNhbndHNXk4QzdjWFpvNUFYTWFiSmlkMzZ0QmZ3QmNTNXFLSWQtV2E1ZnpCck5hQzVvQ1o2LWQzS2M3LXJhc2ZRdTNOVXFwUFpCRmk4NGYtSE9UOXF3RkNlbjdRWGx1M0xYSDh1UlYyOFRBQ2Q0bC1wOEs2RQ?oc=5\" target=\"_blank\">Plus Therapeutics (PSTV) Falls After Mixed Q2 Results and Secondary Offering</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">GuruFocus</font>", "publishedAt": "Fri, 15 Aug 2025 11:57:22 GMT"}, {"title": "Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights | PSTV Stock News - GuruFocus", "description": "<a href=\"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPZXIwNFFnU1pkMnp1TmI0eUZlYmZQRllXN1B6WGVWS0lJLVRyMnlDOG1oNDZYMHA3Q18tY3VOSTU5akJJWDNMbUdZamtPSmJYSElIUzd2VFhLMkNRR0VGZ0J6eTl6TlJhMU9XNlNaeWtqWjJvMV9SV09qZWlNVkpEUk1ZQzhoTDNBck9NeVJsS2lNVUk4c2txXzViakxDdl9hZU5Vdy1hWHNneWNYMWhDMU9xcFRJWU9WQlhVWlpUQlJ0bzBUanRIODdkY0l3TVowa3NCSnVMNnNMRnFx?oc=5\" target=\"_blank\">Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights | PSTV Stock News</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">GuruFocus</font>", "publishedAt": "Thu, 14 Aug 2025 20:36:58 GMT"}, {"title": "Plus Therapeutics Reports Strong Q2 2025 Results - TipRanks", "description": "<a href=\"https://news.google.com/rss/articles/CBMiogFBVV95cUxOLWR6bWlUaWJpUjVQdzcxZ3l6V0VwZWRsbGlEMFBhMnVpOVFkbUxiZkNEUGVyT0oyUXA3SmdVQzZmQWI0QVRERlFMM1hmc01zbUQwT3hJTkFrSG8wTEhJQ3VOdVJvWE9lTW8yblNNZUI1bm1MdUNQd0txMWd6UjJTXzNLUEFzaVBWd3kzLWY4RTJSd09fd3lrcDB3cDljd2RYTGc?oc=5\" target=\"_blank\">Plus Therapeutics Reports Strong Q2 2025 Results</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TipRanks</font>", "publishedAt": "Fri, 15 Aug 2025 05:10:22 GMT"}, {"title": "Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements | PSTV Stock News - GuruFocus", "description": "<a href=\"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNUjNyVjNlSmN3VWtjZEJpTE9OUnhoakxpYzh2ZWpPamxrQXVPQ0R2RUlLaEJvZVJrX2FoT0lZdDNrRVJaUld2bGZWcDREZTF1cjMxc0llMnNYbUwzREVIT0p2UEt5bm1TM21BQ2tHdjhTVzVNN0lUODQ3LXNlWHlLd1FUYjhUeWs3Tlg0SEpLX09LZWdPS1c0Nnd6QWhVTURUWWtJdTBzS0RiUk1xbWNfTUZSMXN3WEhuNzI4U2J0X2l5dnhSdW9uazF1T1NRbF9OQ3BwcnEzT2xFck1QRW12SEpnUmRVTG5idkdfR2Y2ZnE1S2dZVVk1SnNpWDZiQQ?oc=5\" target=\"_blank\">Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements | PSTV Stock News</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">GuruFocus</font>", "publishedAt": "Fri, 15 Aug 2025 11:45:45 GMT"}, {"title": "Plus Therapeutics Approves Key Proposals at Annual Meeting: A Strategic Move to Strengthen Financial Position and Operational Flexibility - AInvest", "description": "<a href=\"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQTmVVN0UzNlphU3I1ZlQ0SGF4TVpwV2d6MFdBNlZpWmNSZEtkX0JSaXlETE9PTS1KYzdJYnNDSUprNEdzbTlWakhtMW9FOXVIc1NpUDdDUjdLU2JCT3h6U2o1blhHZjljTTBmQWNXdWRvelA4WXNQS0tSU050NGRTUVZQZWtDdi1FZnM5VTZCV2tkUUdCY3VvcTlJQ2tPbVUzUTJGcS10aFE2WEwyRi11cG4wcnBmWkR1TDdCMVhaV0ZMYWRrZGZ3WWxBZzc0M0E5OGI3R09SdVVrWGs3UVY1dWpodVF2dzZMZWc?oc=5\" target=\"_blank\">Plus Therapeutics Approves Key Proposals at Annual Meeting: A Strategic Move to Strengthen Financial Position and Operational Flexibility</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">AInvest</font>", "publishedAt": "Wed, 13 Aug 2025 02:24:22 GMT"}, {"title": "The Oncology Institute, Inc. shares rise 1.06% after-hours following Plus Therapeutics' positive CNSide CSF Assay data presentation. - AInvest", "description": "<a href=\"https://news.google.com/rss/articles/CBMizgFBVV95cUxPaWlHcjBoLXBtOVRuUmFuUnBaLTZvSjFJTGdBRkh2bV9waktZbGowanpYdlNNYWdhUnFXN3NjYllfZFRYMHhNbWVEcFoxOGxnNmlUWndqZEQwQy1OQVhrRXNNaVBQVDlVb3ZiQWtQQkJ0ZjNlaVRGZmlvQkdiM2xpYnc2Y0tqbHU1SWRGX0NGMGhkdldlQWc5eEotaWhnaVl2Mi1INWk0akJvQlgyMUZJZ1Itcmd6cDd3U0ZaMkNSVGQ5UmpNcXA1RnpmU3Y5UQ?oc=5\" target=\"_blank\">The Oncology Institute, Inc. shares rise 1.06% after-hours following Plus Therapeutics' positive CNSide CSF Assay data presentation.</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">AInvest</font>", "publishedAt": "Fri, 15 Aug 2025 20:30:12 GMT"}, {"title": "Plus Therapeutics shares fall 6.79% intraday after presenting positive CNSide CSF Assay data. - AInvest", "description": "<a href=\"https://news.google.com/rss/articles/CBMitgFBVV95cUxNdlZkSFA2OFpBYjl6SFdRbFRrSVVNMDVQN3J2SE1Rei1qeFNQbVB1WmFDZWhVTzBJc0xwemkxTy1wRndmdjdoS19RM2lVRzRSNHE1eXc2MzVpYXNVNWJOV3NDZmpzVjBORS1ZMnA2ckV1dmFWUUtHWEhKOXFxLVdtdldlNFJuZDJmYnJianJGMjk2bnZjTV9VbEMybU5aZno4S2VGeTZ4YkUyTlM4NVB5UVhZWnlBUQ?oc=5\" target=\"_blank\">Plus Therapeutics shares fall 6.79% intraday after presenting positive CNSide CSF Assay data.</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">AInvest</font>", "publishedAt": "Thu, 14 Aug 2025 17:07:17 GMT"}, {"title": "Plus Therapeutics Reports $3M in Stock Equity - Baystreet.ca", "description": "<a href=\"https://news.google.com/rss/articles/CBMijgFBVV95cUxQRDBCQXgwZmQyTjJxeExjdHlUXzF5Q0djTkU5ekc0ZHRkWVZBZkowSXU5bWI1dHRfQ0ZOM19rTWhnZ2JXdS1aUVFYeXRudWJtRi1JS0lZUDBhbXZqTjRSZnlFMldrZWo2cWtHM3J5WnBVMWl3XzdhUzc4cWFYV0d5d2IyMEFRZGxhOHNfWV9B0gF4QVVfeXFMTUloUnFTU0xNRUU1S0gyTk5mQnk0M1Yta2VjS2R3VTBUYW9vbHppNFdaXzhmakFFV28zbWgwdVN4UHZ0ZkptYTZXS2w4cmZvV0ZYV2VoVDhIdFRmVGRYckxQWkYzZXg3bXZKUzhTRTJVS1gwREtYaDI1?oc=5\" target=\"_blank\">Plus Therapeutics Reports $3M in Stock Equity</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Baystreet.ca</font>", "publishedAt": "Fri, 15 Aug 2025 13:46:00 GMT"}, {"title": "What\u2019s the recovery path for long term holders of Plus Therapeutics Inc. - Trade Analysis Summary & Capital Efficiency Focused Strategies - Newser", "description": "<a href=\"https://news.google.com/rss/articles/CBMisAFBVV95cUxOb1ZibFJRZ0RjWE5zSTVFa25DZXRzSThITm5BNEJWTHhaajRYeHhtbTVqbG15TVdpM0M2RnktYXRUNk5NNmQyTXl6aHg2OHdqOERKM0hzU2pIR3Z1WVM0eUZabDhwOWl5cDZlQjFZYXNaMnhNYnVhZ1g3QXNrcTB5NndXYVliQ1FCZmNLUm5reFVrV1RSV1pKZG42d1NxM19iRlYxOHFnZ1BSUFo2WnFnTw?oc=5\" target=\"_blank\">What\u2019s the recovery path for long term holders of Plus Therapeutics Inc. - Trade Analysis Summary & Capital Efficiency Focused Strategies</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Newser</font>", "publishedAt": "Fri, 15 Aug 2025 20:17:16 GMT"}, {"title": "Plus Therapeutics Inc. stock trend forecast - 2025 Institutional Moves & Fast Moving Market Watchlists - Newser", "description": "<a href=\"https://news.google.com/rss/articles/CBMigwFBVV95cUxPd3ZKS1pfdkFLZ3hYZ1c3Z2Zidl9rM0V1c1VHMlExRGw2MEpQczFLbTFQM0MxbU95b2g2TnlJT2h4bk5md3dMMTZqUVB5b1ZWTk1JMmpCNVc5V1lhZmtDUXBJc2puS1JDaV9Rb0UwRHJKWDV5cEVCUUZ2SVhwbF9wX1BVbw?oc=5\" target=\"_blank\">Plus Therapeutics Inc. stock trend forecast - 2025 Institutional Moves & Fast Moving Market Watchlists</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Newser</font>", "publishedAt": "Sat, 16 Aug 2025 11:36:50 GMT"}, {"title": "How sentiment analysis helps forecast Plus Therapeutics Inc. - July 2025 Intraday Action & Growth Oriented Trade Recommendations - Newser", "description": "<a href=\"https://news.google.com/rss/articles/CBMimgFBVV95cUxPTzVTcWpYX0ZHeWNpQzdIbTF1cmU0ay1rMUJFT0daWkREUV90UXJTNmVXcUNFTU9VNlltWDJHaDZiRUo1eml3YlZ5SGt4RW9YdjFTYzhsbkgzVFAzZzhCMDEyTFZsc2c0T0Fhc3BrcUdjU0xnWUF4VDQ1Ml9wQ1diQWsxLWRUSjJmdmpoX3AwT3lVRTR1bnZrd3dR?oc=5\" target=\"_blank\">How sentiment analysis helps forecast Plus Therapeutics Inc. - July 2025 Intraday Action & Growth Oriented Trade Recommendations</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Newser</font>", "publishedAt": "Sat, 16 Aug 2025 06:10:19 GMT"}, {"title": "Competitive Positioning of Plus Therapeutics Inc.: Is It Leading or Lagging - Newser", "description": "<a href=\"https://news.google.com/rss/articles/CBMipwFBVV95cUxOY3VzRzVFaEpjeW45aW5ZRERxOXdhaGF1M09PQlpKZW5rRHpwV2RLcTJlTFV1SmR2ZnhOMmZIeWdvQjJSeDRmVFg1WjQzSVl5cTlSN3RkZXhUQ3JJYlVjUGZoOEU2RmtGMUc1WTZIQkNCa2dZelZHUC1JZ3ItWFJCN2Nkb1V5YVdUSlZOMGpZYlFDSVloRHgxWVhJd3prOWRxS1dITjVNMA?oc=5\" target=\"_blank\">Competitive Positioning of Plus Therapeutics Inc.: Is It Leading or Lagging</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Newser</font>", "publishedAt": "Fri, 15 Aug 2025 21:27:52 GMT"}, {"title": "Plus Therapeutics Inc. stock trend forecast - Dollar Strength & Fast Moving Stock Trade Plans - Newser", "description": "<a href=\"https://news.google.com/rss/articles/CBMifEFVX3lxTE5EdnNUOHZpZXh4cUlaeXBIWEltQ2U4a0Z0LUNycnhDWWtPaUt2ei1rblBpbjRRMHpIbm1WbGNYOVNIN0xyS3hmaGpuYkY2YUtnZE40WUtwRE82Nm9McVRMNXIzb1Zpc1hibkMzRmdrQ21NOUpzQkNXa1F0NXY?oc=5\" target=\"_blank\">Plus Therapeutics Inc. stock trend forecast - Dollar Strength & Fast Moving Stock Trade Plans</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Newser</font>", "publishedAt": "Sat, 16 Aug 2025 09:50:07 GMT"}, {"title": "How Plus Therapeutics Inc. stock performs during market volatility - Free Market Entry and Exit Point Tips - Newser", "description": "<a href=\"https://news.google.com/rss/articles/CBMilgFBVV95cUxPLUJncjNKcmc4a2ZGTEZUQ0NGVlZ1RUtsQVdWbXlERkVJdTBwYkp1b1BCbVJKQXZraUxRYjloLUYyblpTMFd6QlBoam55bkN5aVBDYmljV3d5bVdPRXJTZ2NlYm1LbENJcm1HU1c0MkhHUmlST25vYWJ2SXZlcUk3YU1fbU44QldzVzlRZ3BlTTNYSWU5TEE?oc=5\" target=\"_blank\">How Plus Therapeutics Inc. stock performs during market volatility - Free Market Entry and Exit Point Tips</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Newser</font>", "publishedAt": "Mon, 11 Aug 2025 01:13:23 GMT"}]